[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National University of Singapore\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":738},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,52,80,124,155,179,205,231,258,290,316,350,376,403,431,459,484,525,554,585,611,638,657,680,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100627087","assessing-biological-aging-in-a-real-world-medical-weight-loss-program-using-the-linage2-clinical-clock-100627087",false,"NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","Inclusion Criteria\n\n* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.\n* BMI of ≥ 30 kg\u002Fm2 (obesity); OR\n* BMI of ≥ 27 kg\u002Fm2 to \\\u003C 30 kg\u002Fm2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n\nExclusion Criteria\n\n* Pregnancy or lactation.\n* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.\n* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.\n* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.\n* Active cancer on chemotherapy or immunotherapy.\n* Known hypersensitivity or contraindications to GLP-1 RAs.\n* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.","ALL","40 Years","89 Years",{"count":20,"type":21},440,"ESTIMATED","OBSERVATIONAL","This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.",[25,26],"Aging","Obesity & Overweight",[28,29,30,31,32,33,34,35,36,37,38],"LinAge2","Biological Age","GLP-1 Receptor Agonist","Semaglutide","Tirzepatide","Weight Management Program","Lifestyle","Real-World Evidence","Cardiometabolic Biomarkers","Body Composition","Prospective Cohort","NOT_YET_RECRUITING","2026-06-29",{"date":42,"type":43},"2026-07-01","ACTUAL",{"date":45,"type":21},"2026-06-01",{"date":47,"type":21},"2027-12-31",{"name":49,"class":50},"National University of Singapore","OTHER",2,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100642515","cross-cultural-differences-in-sleep-patterns-and-problems-in-asian-school-aged-adolescents-the-across-study-100642515","NCT07577882","Cross-cultural Differences In Sleep Patterns And Problems in Asian School-aged Adolescents: The ACROSS Study","ACROSS","Inclusion Criteria:\n\n* School-going adolescents aged 12-18 years old\n\nExclusion Criteria:\n\n* Nil.",true,"12 Years","18 Years",{"count":63,"type":21},15000,"Sleep problems are common in adolescents. Studies have consistently demonstrated that sleep disturbances are prevalent, affecting up to 50% of this population. In this project, the investigators aim to map out sleep patterns, risk factors, and obstacles for sleep in adolescents, capturing the diversity of societal factors that shape the sleeping habits of adolescents. The investigators aim to recruit school-aged adolescents (aged 12-18 years old) in 12 countries across 15 research centres (N = 1000 per centre) to fill in the questionnaire covering sleep-wake patterns, sleep problems, mood, behavioral, daytime functioning and their attitude and perception towards sleep.",[66,67],"Characterise Sleep Patterns Across Asia","Examine Barriers to Sleep",[69,70,71],"Adolescents","Sleep","Cross-cultural","2026-06-11",{"date":74,"type":43},"2026-06-15",{"date":76,"type":21},"2026-07",{"date":78,"type":21},"2026-12",{"name":49,"class":50},{"id":81,"slug":82,"hasResults":12,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":59,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":104,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100639366","investigating-the-effect-of-caffeine-and-alcohol-on-pupil-dynamics-100639366","NCT07625358","Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics","Investigating the Effect of Caffeine and Alcohol on Pupil Dynamics (PAC)","PAC","Participants must meet the inclusion criteria, as shown below, to participate in this study\n\nInclusion Criteria\n\n1. Age: 30 to 50 years of age\n2. Visual Acuity: Best Corrected Visual Acuity (BCVA) of 0.20 LogMAR or better in both eyes\n3. Ability to provide informed consent: Participants must be able to understand and sign the informed consent form\n4. Ability to consume both caffeine and alcohol: Participants must be willing and able to consume caffeine and alcohol as part of the study\n\nParticipants meeting any of the exclusion criteria, as shown in the table below, will be excluded from participation.\n\nExclusion Criteria\n\n1. Diagnosed ocular conditions: Participants with ocular or ocular movement diseases such as glaucoma, age-related macular degeneration, diabetic retinopathy, amblyopia, severe ptosis, or conditions relating to pupils: anisocoria, irregular pupil, Adie tonic, Horner's syndrome, Argyll Robertson pupil, etc. These exclude cataracts, refractive errors, and any ocular condition not affecting vision or ocular movement or obstructing the pupil.\n2. Diagnosed and unresolved neurological conditions:Stroke, unresolved traumatic brain injury, space-occupying lesions in the brain, neuropathies, demyelinating conditions, nerve palsies, etc.\n3. Diagnosed systemic conditions that may restrict the participant from drinking caffeine or alcohol: Hypertension, cardiovascular disease, liver disease, kidney disease, etc.\n4. Medications: Participants taking any medications that may interact with caffeine or alcohol, affect alertness, or cause drowsiness\n5. Previous complex intraocular eye surgery: Participants who have undergone any eye surgery other than uncomplicated refractive surgery.\n6. Pregnancy or breastfeeding: Pregnant or breastfeeding women will be excluded from the study, as caffeine and alcohol can affect the fetus or baby\n7. History of substance abuse: Participants with a history of substance abuse\n8. Allergies or sensitivities: Participants with allergies or sensitivities to caffeine or alcohol\n9. Shift work or having travelled across 2 time zones over the past 2 weeks: This is essential to avoid any impact of sleep deprivation on our outcome measures\n10. Non-consumers or light-consumers of caffeine and alcohol Participants who are light consumers of caffeine or alcohol will be excluded due to higher sensitivity to side effects.\n\nCaffeine: If less than 100 mg of caffeine per week from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\\* Alcohol: If AUDIT-C\\*\\* score less than 1\n\n11- Extremely frequent consumers Participants who are extremely frequent consumers of caffeine or alcohol will be excluded due to potential withdrawal symptoms during the required 18-hour abstinence and possible reduced sensitivity to administered doses.\n\nCaffeine: If more than 400mg of caffeine (e.g., 5 espressos) per day from all sources (including coffee, soft drinks, energy drinks, chocolate, and medications) based on the CCQ\\* Alcohol: If AUDIT-C\\*\\* scores more than 4 for men and more than 3 for women\n\nNote: Participants will complete a history update questionnaire at each laboratory visit to report any changes relevant to the exclusion criteria. If a participant no longer meets the eligibility criteria at any visit after the baseline assessment, the visit will either be rescheduled, if appropriate, or the participant will be withdrawn from the study. Reimbursement will be provided on a prorated basis.\n\n\\*CCQ: Caffeine Consumption Questionnaire\n\n\\*\\*AUDIT-C: Alcohol Use Disorders Identification Test-C","30 Years","50 Years",{"count":91,"type":21},100,"INTERVENTIONAL",[94],"NA","The goal of this study is to understand how caffeine and alcohol affect the ocular and physiological systems, especially how the pupil (the aperture in the colored part of the eye) responds to light. It will also test whether these changes can be used to detect recent caffeine or alcohol intake using a portable eye device.\n\nThe main questions it aims to answer are:\n\n1. How does caffeine change pupil responses, eye movements, and other ocular and physiological measurements?\n2. How does alcohol change these same ocular and physiological responses?\n3. Are the effects of caffeine and alcohol different from each other?\n4. Can these changes be used to accurately identify whether someone has consumed caffeine or alcohol?\n\nResearchers will compare caffeine, alcohol, and a placebo (a look-alike drink with no active substance) to see how each affects the ocular and physiological outcomes.\n\nParticipants will:\n\n1. Attend three separate sessions where they will consume caffeine, alcohol, or a placebo (in random order)\n2. Undergo pupillary response evaluation using a handheld device that measures responses to different colored light stimuli\n3. Have their eye movements analyzed\n4. Have retinal and choroidal thickness, blood perfusion, and ocular oxygen levels measured\n5. Have basic body measurements recorded (such as pulse rate and blood pressure)\n6. Complete tests at multiple time points over 2 hours after consumption\n\nThe results of this study may help develop a quick and non-invasive way to detect recent caffeine or alcohol use for clinical and safety purposes.",[97,98,99,100,101,102,103],"Caffeine","Alcohol","Pupillary Response","Eye Movements","Optical Coherence Tomography","Optical Coherence Tomography Angiography","Physiological Responses",[97,98,105,106,107,108,109,110,111,112,113,114],"Pupillary light reflex","Pupillometry","Chromatic pupillometry","Eye movements","Oculomotor function","Optical coherence tomography","Optical coherence tomography angiography","Physiological responses","Machine learning","Non-invasive monitoring","RECRUITING","2026-05-28",{"date":118,"type":43},"2026-06-04",{"date":45,"type":21},{"date":121,"type":21},"2027-11-05",{"name":49,"class":50},1,{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":92,"phases":134,"briefSummary":135,"conditions":136,"keywords":139,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100633889","internet-based-cognitive-behavioural-therapy-icbt-for-anxiety-and-depression-in-singapore-100633889","NCT07532551","Internet-Based Cognitive Behavioural Therapy (iCBT) for Anxiety and Depression in Singapore","Assessing the Clinical and Cost Effectiveness of Internet-Based Cognitive Behavioural Therapy (iCBT) for Anxiety and Depression in Singapore","1. Quantitative Study - Patients\n\n   Inclusion Criteria:\n   * Age ≥21 years\n   * Tier 2 - 3 depression and\u002For anxiety based on PHQ-9 and GAD-7 scores\n\n     * PHQ-9 score of 5 to 19\n     * GAD-7 score of 5 to 14\n   * Able to provide informed consent\n\n   Exclusion Criteria:\n   * Unable to read or understand English (Primary 6 level)\n   * Unable to use the internet (e.g. due to lack of internet access or insufficient digital literacy)\n   * Does not possess a mobile device or is not able to access the iCBT application\n   * Actively experiencing psychosis\n   * Suspected with personality disorder\n   * Primary concern is obsessive compulsive disorder (OCD)\n   * Tier 4 patients with severe depression or anxiety\n\n     * PHQ-9 score of 20 and above\n     * GAD-7 score of 15 and above\n   * Any suicidal risk or ideation\n\n     * PHQ-9 Question 9 score of more than 2\n2. Qualitative Study - Service Providers\n\nInclusion Criteria:\n\n* Are currently or previously have been involved in the delivery, supervision, or implementation of the iCBT programme\n* Have had direct experience supporting patients enrolled in the study\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Have no direct involvement in the iCBT programme; or\n* Have had insufficient exposure to the programme, defined as managing fewer than one referred case or less than one month of involvement at the time of recruitment.\n* Conflict of interest or Supervisory Hierarchy Concerns - Individuals whose participation may create perceived coercion or introduce bias\n* Inability to provide informed consent","21 Years",{"count":133,"type":21},390,[94],"Cognitive-behavioural therapy (CBT) has a robust evidence base for treating anxiety disorders and depression, including transdiagnostic CBT. Internet-based CBT (iCBT) offers a new approach to delivering these therapies. iCBT is a digital adaptation of traditional CBT that leverages digital platforms to deliver similar therapeutic interventions. iCBT encompasses structured programmes that provide users with tools and techniques to manage mental health issues such as depression and anxiety. The digital format ensures timely access to CBT and typically includes interactive modules, videos, self-assessment tools, and virtual therapist support. This study aims to evaluate the effectiveness of iCBT in reducing symptoms of anxiety and depression, as well as its cost-effectiveness and acceptability in local context.\n\nThe main questions it aims to answer are:\n\n1. Do participants receiving iCBT show a reduction in symptoms of anxiety and\u002For depression, and does the effectiveness of iCBT vary based on individual user characteristics?\n2. What are the factors that influence the acceptance, adoption, and engagement rates of iCBT among Singaporeans?\n3. Is iCBT more cost-effective as compared to usual care?\n\nResearchers will compare guided iCBT to usual care (traditional CBT) to assess iCBT's clinical effectiveness, cost-effectiveness, and acceptability in Singapore's primary and community healthcare settings.\n\nParticipants in the intervention group will:\n\n1. Undergo guided iCBT intervention consisting of 8 weeks of online modules covering core CBT techniques\n2. Counsellors will schedule 3 regular check-ins\n3. Questionnaires will be administered at 5 timepoints\n4. Selected participants will be invited for a semi-structured interview to assess their experiences with iCBT\n\nParticipants in the control group will:\n\n1. Continue usual care\n2. Questionnaires will be administered at 5 timepoints\n\nA parallel qualitative study involving service providers is required to contextualise trial findings, identify implementation barriers and enablers and inform national scale-up and policy decisions. It aims to explore service providers' experiences, perceptions and contextual factors influencing the implementation of iCBT within routine primary-care and community mental-health services participating in this trial.",[137,138],"Depression and\u002For Anxiety in the Mild-to-moderate Range","Cognitive Behavioral Therapy",[140,141,142,143,144,145],"internet-delivered cognitive behavioural therapy","cognitive behavioural therapy","CBT","iCBT","anxiety","depression","2026-04-12",{"date":148,"type":43},"2026-04-16",{"date":150,"type":21},"2026-04",{"date":152,"type":21},"2028-03",{"name":49,"class":50},3,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":92,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100633736","a-health-coach-led-digital-lifestyle-intervention-healdi-100633736","NCT07530562","A Health Coach-Led Digital Lifestyle Intervention (HEALDI)","A Health Coach-Led Digital Lifestyle Intervention (HEALDI) for the Regression of Diffuse Myocardial Fibrosis: A Randomised Controlled Trial","Inclusion Criteria:\n\n* Left ventricular hypertrophy on cardiovascular magnetic resonance based on local age and sex specific criteria\n* Age 40-70 years old\n* Has internet access\n* Owns and uses a smartphone daily\n* Able to converse and comprehend the English or Chinese language\n\nExclusion Criteria:\n\n* History of major cardiovascular events (MACE), which is defined as coronary heart disease death, non-fatal myocardial infarction, stroke\n* Diagnosed with secondary causes of hypertension (E.g., renal causes - renal artery stenosis, chronic renal failure; endocrine causes- pheochromocytoma, Cushing's syndrome, hyperthyroidism; cardiac causes - coarctation of the aorta)\n* Diagnosed with significant coronary artery disease with previous percutaneous intervention or coronary artery bypass surgeries\n* Diagnosed with cardiac arrhythmias such as atrial fibrillation and frequent premature ventricular contractions\n* Diagnosed with inherited\u002Facquired cardiomyopathies (E.g., hypertrophic cardiomyopathy, dilated cardiomyopathy)\n* Diagnosed with infiltrative disease (E.g., cardiac amyloid, cardiac sarcoid)\n* Contraindications to Brain and Cardiac Magnetic Resonance or gadolinium contrast (E.g., renal failure- eGFR \\\u003C30ml\u002Fmin\u002Fm2 or documented contrast allergy; implantable devices such as cardiac pacemakers, brain aneurysms or clips, metal implants (including braces), foreign bodies in the eye; claustrophobia; end organ failure; women who are pregnant or breast-feeding)\n* Any pre-existing medical conditions or disabilities that limits their participation in lifestyle interventions (E.g., Dementia)\n* Individuals who have achieved the Singapore physical activity guideline of 150 minutes of moderate intensity exercise or 75 minutes of vigorous intensity exercise per week or an equivalent combination per week\n* Limited life expectancy of less than 12 months\n* Participating in other research projects involving behavioural therapy or changes related to physical activity","70 Years",{"count":164,"type":21},200,[94],"Aim: To evaluate the effectiveness of an artificial intelligence (AI)-assisted 12-month Health Coach-Led Digital Lifestyle Intervention (HEALDI) versus control on diffuse myocardial fibrosis and ambulatory blood pressure in individuals with hypertensive heart disease (HHD), with secondary outcomes including multi-organ health parameters, health behaviours, social support, psychological health, and health-related quality of life.\n\nBackground: The global prevalence of hypertensive heart disease (HHD) has increased approximately 1.5-fold, from 7.82 million cases in 1990 to 12.50 million in 2021, and it is now the second leading cause of heart failure worldwide. In HHD, chronic pressure overload drives fibroblast activation and interstitial collagen deposition, leading to diffuse myocardial fibrosis which is associated with cardiac dysfunction, arrhythmias, impaired coronary flow reserve, and an increased risk of sudden cardiac death and heart failure. Although diffuse myocardial fibrosis is potentially reversible, no approved anti-fibrotic pharmacological therapy currently exists. Furthermore, there is limited evidence evaluating the effectiveness of lifestyle interventions, particularly aerobic exercise, in reversing diffuse myocardial fibrosis.\n\nDesign: A parallel, single-blinded two-arm randomised controlled trial.\n\nMethod: This study is a randomised controlled trial with repeated measures, recruiting 200 physically inactive individuals with HHD from the community, including participants from Project RESET, a community-based cohort study in Singapore. Participants will be randomly allocated to either the intervention or control group.\n\nParticipants in the intervention group will receive the 12-month HEALDI intervention, which includes the HEALDI mobile application, wearable device, and remote health coaching. Participants in the control group will receive a wearable device and a basic mobile application without intervention features, used solely for data collection.\n\nData will be collected at baseline (upon randomisation) and at 6, 12 and 24 months. A process evaluation will be conducted using intervention engagement data. In addition, semi-structured interviews with participants and health coaches will explore perceptions of the intervention and behaviour change. A within-trial economic evaluation, from both healthcare system and societal perspectives, will be performed to assess cost-effectiveness.\n\nSignificance: This study will generate insights into the role of lifestyle modification as a complementary, non-pharmacological strategy alongside pharmacotherapy to halt or slow HHD progression, improving long-term cardiovascular outcomes.",[168,169,170,171],"Myocardial Fibrosis","Left Ventricle Hypertrophy","Hypertensive Disease","Hypertension","2026-04-08",{"date":174,"type":43},"2026-04-15",{"date":150,"type":21},{"date":177,"type":21},"2028-06",{"name":49,"class":50},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":59,"sex":16,"minAge":131,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":92,"phases":188,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":123},"100621810","community-based-mobile-assisted-brief-intervention-for-smoking-cessation-100621810","NCT07375459","Community-based Mobile-assisted Brief Intervention for Smoking Cessation","Mobile-assisted Brief Intervention for Smoking Cessation in Community-based Setting: a Pilot Randomised Controlled Trial","Inclusion Criteria:\n\n* Aged 21 to 80 years\n* Smoked at least one cigarette daily\n* Able to communicate and read in English or Chinese\n* Own a smartphone with WhatsApp installed\n\nExclusion Criteria:\n\n* Exposed to any smoking cessation treatment in the past 3 months\n* Pregnant women","80 Years",{"count":91,"type":21},[94],"The goal of this pilot trial is to evaluate the feasibility of a mobile-assisted brief intervention for smoking cessation in community-based individuals in Singapore. Specific aims include:\n\n1. To assess how many eligible individuals accept the invitation to participate in the trial\n2. To assess the retention of the participants through 6 months after treatment initiation\n3. To assess the acceptability of the intervention in terms of participants' engagement and ratings\n4. To examine the intervention effect on abstinence outcomes\n\nParticipants will be randomly assigned to either the intervention group or control group and followed for 6 months from randomisation.",[191],"Smoking &Amp; Tobacco Cessation",[193,194,195,196,197],"mHealth","WhatsApp","smoking cessation","chat-based intervention","Singapore",{"date":199,"type":43},"2026-04-09",{"date":201,"type":43},"2026-02-04",{"date":203,"type":21},"2027-03-31",{"name":49,"class":50},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":59,"sex":16,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":4,"studyType":92,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":51},"100566923","evidence-based-lifestyle-interventions-for-the-delay-of-cognitive-decline-among-older-singaporeans-100566923","NCT06661486","Evidence-based Lifestyle Interventions for the Delay of Cognitive Decline Among Older Singaporeans","Evidence-based Lifestyle Interventions for the Delay of Cognitive Decline Among Older Singaporeans: Cohort Study and Randomized Controlled Trial","Inclusion Criteria:\n\n* (1) Age 60-75 years;\n* (2) Singapore Modified Mini-Mental State Examination total score lower than locally validated education-specific cutoffs: \\< 25, 27 and 29 for those with nil, primary and secondary school and above education levels, respectively66.\n* (3) Non-demented (Clinical Dementia Rating global score = 0).\n\nExclusion Criteria:\n\nConditions preventing effective engagement in the intervention\n\n* (1) Terminal illness, aphasia\n* (2) Marked hearing impairment\n* (3) Participation in another interventional study","60 Years","75 Years",{"count":215,"type":21},120,[94],"The investigators aim to investigate the relationship between lifestyle factors and cognitive decline among older Singaporeans and assess the feasibility and preliminary efficacy of a lifestyle intervention programme in delaying cognitive decline. Healthy lifestyle is a way of living that can lower down disease risk and promote health and wellbeing. Accumulating evidences support that lifestyle factors contribute to the development of dementia and hence modifying lifestyle could be a promising approach for dementia prevention. The intervention will focus on the promotion of a brain-healthy lifestyle, with special attention paid to common problems among local older adults. The investigators will assess cognitive and biological changes using the following outcome measures. Primary outcome: the processing speed domain Z score derived from raw scores of three tests including the symbol digit modality test, Colour trial test, and Stroop test (condition 2). Secondary outcome: i. epigenetic age (DNA methylation), ii. plasma-based markers of inflammation, iii. activities of daily living and instrumental activities of daily living, iv. Health-related quality of life measured by the EQ-5D-5L scale, v. wellbeing measured by the ICECAP-O (ICEpop CAPability measure for Older people), vi. other neurocognitive assessment tests. The investigators hypothesize that:\n\n1. Lifestyle factors are associated with cognitive decline, epigenetic age, and systematic chronic inflammation.\n2. Evidence-based lifestyle intervention focusing on common problems among local population can delay cognitive decline, slow epigenetic ageing, and produce favorable changes on chronic systemic inflammation.\n3. Changes in biological markers will correlate with changes in cognitive function, and hence partially explains the observed clinical efficacy.\n4. The interventions may also improve daily functioning, health-related quality of life, and wellbeing.\n5. Interventions delivered in an individualized manner would produce more benefits than interventions delivered uniformly without considering individual's risk profile and personal and social context.",[219],"Non Demented",[221,222,223],"Lifestyle Intervention","MMSE","CDR","2026-04-07",{"date":172,"type":43},{"date":227,"type":43},"2024-10-01",{"date":229,"type":21},"2028-04",{"name":49,"class":50},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":59,"sex":16,"minAge":17,"maxAge":212,"enrollmentInfo":238,"targetDuration":4,"studyType":92,"phases":240,"briefSummary":241,"conditions":242,"keywords":247,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":123},"100633346","die-logue-program-for-community-dwelling-adults-a-randomized-controlled-trial-100633346","NCT07525492","Die-logue Program for Community Dwelling Adults: A Randomized Controlled Trial","Effects of a Die-logue Program in Enhancing Community Dwelling Adults's Death Attitudes, Coping With Death and Readiness for Advance Care Planning: A Two-phase Study","Inclusion Criteria:\n\n* Between the ages of 40 to 60 years\n* Able to comprehend the English language\n* Have not completed any form of advance directives\n* Able and willing to participate in the Die-logue programme and surveys\n\nExclusion Criteria:\n\n* Individuals diagnosed with any life limiting diseases\n* Individuals with self-reported history of mental health disorders or neurological disorders",{"count":239,"type":21},148,[94],"The goal of this clinical trial is to evaluate whether the Die-logue program can improve attitudes toward death, coping with death, and readiness for advance care planning (ACP) among community-dwelling middle-aged adults aged 40-60 years who have not completed any advance directives and not diagnosed with any life limiting diseases.\n\nThis study aims to address the following research questions:\n\n* Does the Die-logue program improve community-dwelling middle-aged adults' attitudes towards death, ability to cope with death, readiness and uptake for Advanced Care Planning (ACP).\n* What are community-dwelling middle-aged adults' perceptions of advance care planning, death and dying, and their experiences of participation in the Die-logue program.\n\nResearchers will compare participants who receive the Die-logue program (death conversation and online ACP education) with participants who receive only the online ACP education to see if informal death conversations improve attitudes toward death, coping with death, and readiness for ACP.\n\nParticipants will:\n\n* Complete online questionnaires measuring attitudes toward death, coping with death, and readiness for advance care planning.\n* Participate in a facilitator-led group discussion session about perceptions of death, coping with death, and readiness for ACP (intervention group only).\n* Complete an asynchronous online ACP education session consisting of short recorded videos and an online discussion forum (both intervention and control group).\n* Complete follow-up surveys, including a 6-month follow-up assessing whether they have undertaken advance care planning.",[243,244,245,246],"Death Attitude (Implicit\u002FExplicit)","Death Anxiety","End of Life Care","Advanced Care Planning (ACP)",[248,244,249,250],"Death Conversation","Advance Care Planning","Death Attitude","2026-04-06",{"date":253,"type":43},"2026-04-13",{"date":255,"type":21},"2026-04-01",{"date":47,"type":21},{"name":49,"class":50},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":264,"eligibilityCriteria":265,"healthyVolunteers":59,"sex":16,"minAge":131,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":92,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":51},"100632896","frailty-improvement-through-technology-with-informal-caregiver-supported-exercise-fitwise-for-pre-frail-and-frail-community-dwelling-older-adults-100632896","NCT07519642","Frailty Improvement Through Technology With Informal Caregiver Supported Exercise (FITWISE) for Pre-frail and Frail Community-dwelling Older Adults","The Development and Feasibility Testing of a Caregiver-mediated, Technology-facilitated, Home-based Frail Intervention Program (FITWISE) for Pre-frail and Frail Community-dwelling Older Adults: a Three-arm Pilot Randomized Controlled Trial","FITWISE","1. For Participants:\n\n   Inclusion Criteria:\n   * Recruited from Lions Befrienders Active Aging Centres (AACs) or Tzu Chi Active Aging Centres (AACs)\n   * Aged 60 to 99 years\n   * Clinical Frailty Scale (CFS) score of 3 to 5\n   * Identified by the active aging centre as inactive in centre and community activities\n   * Able to provide valid informed consent\n   * Able to communicate in and read Chinese or English\n   * Living in their own homes and not in residential care\n   * Willing to allow home visits by the research team\n   * Residing in a home environment assessed as safe for exercise (e.g., adequate space and minimal environmental fall hazards)\n\n   Exclusion Criteria:\n   * Significant cognitive impairment or mental health conditions that prevent understanding of the study or safe participation in the exergaming activity (e.g., moderate to severe Alzheimer's disease)\n   * Pre-existing medical conditions that prohibit exercise or are hemodynamically unstable (e.g., end-stage heart failure)\n   * Physical limitations that hinder participation (e.g., wheelchair-bound)\n   * Severe visual or hearing impairments that would interfere with participation\n   * Experiencing severe pain that limits participation\n   * Currently participating in another regular vigorous exercise program\n   * Refusal to consent to video recording required for the exergaming system\n2. For Informal Caregiver\n\nInclusion Criteria:\n\n* Spouse, partner, child, relative, friend, or neighbor of the participant who provides unpaid support\n* Living with the participant or living separately\n* Aged 21 to 99 years\n* Able to communicate in and read English or Chinese\n* Living with the participant or willing to visit the participant two to three times per week to support the intervention\n* Cognitively fit as indicated by a Montreal Cognitive Assessment (MoCA) score above the normal cutoff\n* Assessed by the research team to be suitable for delivering the intervention\n\nExclusion Criteria:\n\n\\- Paid caregivers, such as healthcare professionals or foreign domestic helpers.","99 Years",{"count":268,"type":21},60,[94],"The goal of this pilot trial is to evaluate the feasibility and potential effectiveness of a caregiver-mediated, technology-facilitated home-based intervention named Frailty Improvement through Technology With Informal Caregiver Supported Exercise (FITWISE) for pre-frail and frail community-dwelling older adults aged 60 years and older.\n\nFrailty is associated with reduced physical function, increased risk of falls, and higher healthcare utilization among older adults. Home-based interventions supported by informal caregivers and facilitated by digital technology may help improve exercise participation and health outcomes in this population.\n\nThe main questions this study aims to answer are:\n\n1. Whether the FITWISE intervention is feasible in terms of recruitment, participant engagement, adherence, retention, and safety.\n2. Whether the FITWISE intervention improves physical performance and other health-related outcomes among pre-frail and frail community-dwelling older adults.\n\nResearchers will compare two intervention groups with a control group to determine whether the FITWISE intervention improves health outcomes.\n\nParticipants will be randomly assigned to one of three groups:\n\n* Intervention Group A: Caregiver-mediated multi-component exercise supported by an exergaming system.\n* Intervention Group B: The same exercise program with additional caregiver-delivered psychosocial support.\n* Control Group: General health education and usual activities without the FITWISE intervention.\n\nThe intervention will last 24 weeks and will include an active 12-week intervention phase followed by a 12-week maintenance phase. Outcome measures such as physical performance, frailty status, cognitive function, social support, quality of life, and selected health indicators will be assessed at baseline and after the intervention.",[272,273],"Frailty","Pre-Frailty",[272,275,276,277,278,279,280,281,282,283],"Pre-frailty","Older adults","Caregiver-mediated exercise interventions","Home-based exercise","Artificial intelligence","Exergame","Multicomponent exercise","Community-dwelling older adults","Digital health intervention",{"date":199,"type":43},{"date":286,"type":21},"2027-02-01",{"date":288,"type":21},"2028-06-30",{"name":49,"class":50},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":59,"sex":16,"minAge":297,"maxAge":60,"enrollmentInfo":298,"targetDuration":4,"studyType":92,"phases":300,"briefSummary":301,"conditions":302,"keywords":305,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":123},"100512741","personalising-childrens-screen-use-reduction-for-better-sleep-mental-and-brain-health-100512741","NCT05956392","Personalising Children's Screen Use Reduction for Better Sleep, Mental, and Brain Health","Reducing Children's Screen Use for Better Sleep, Mental, and Brain Health: a Personalised Approach","Inclusion Criteria:\n\n* Is a Singaporean or Permanent Resident\n* Speaks English\n* Aged between 6-12 years old\n* Habitually sleeps less than 8 hours during school nights\n* Habitually spends more than 2 hours on media use (i.e. social media, gaming, and TV \u002F videos) on school days\n* Is not on any long-term medications\n* Has no known medical or developmental conditions that could affect sleep (e.g. asthma, arthritis, cancer, congenital heart disease, diabetes, epilepsy, eczema, inflammation)\n* Has no history of psychiatric or neurological disorders\n\nExclusion Criteria:\n\n\\-","6 Years",{"count":299,"type":21},150,[94],"In Singapore, 64.4% of school-age children sleep less than the minimum recommended duration of 9 hours on school nights, thus risking poor mental, cognitive, and brain health. These short-sleeping children, however, spend on average 2.5 hours per school day on non-academic media use, revealing the potential of reducing their screen time for more sleep. Previous interventions targeted at reducing media use and\u002For improving sleep among school-age children, though effective in increasing sleep, required cooperation from schools, extensive personnel training, and high commitment of participants, rendering them difficult to implement in Singapore. Existing interventions also focused on evening or pre-bedtime screen use, and took a one-size-fits-all approach, ignoring individual differences in the duration, type, and purpose of media use throughout the day. Here, we propose a scalable approach to curtail media use based on individual need throughout the day. We will conduct a randomised controlled trial during term time, recruiting 150 children, aged 6-12 years, who on school days, sleep less than 8 hours and spend more than 2 hours on media use. At baseline, all participants will record their time use patterns. The research staff will then help the intervention group to repurpose at least 60 minutes of media use per school day for sleep. Importantly, participants can decide the type, timing and duration of media use to curtail, thus giving them a sense of agency and mastery, while boosting their self-efficacy, a vital ingredient in behavioural change. The intervention group will follow this personalised schedule for 2 weeks, while the control group will be in a free-living condition. Two weeks after the intervention has ended, the intervention group will undergo follow-up assessments. Throughout the study, sleep, time use, cognitive functions, and psychological well-being will be assessed daily. Other cognitive tasks and questionnaires will be conducted during 2-3 lab\u002Fschool-classroom visits, with one-third of the participants also undergoing high-density electroencephalography to measure brain activity.",[303,304],"Screen-use Reduction + Sleep Extension","Free-living",[306,307,308,309,310],"Cognitive Functions","Neurobehavioural Functions","Sleep Duration","Screen-use","High-density EEG",{"date":253,"type":43},{"date":313,"type":43},"2023-07-03",{"date":47,"type":21},{"name":49,"class":50},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":92,"phases":325,"briefSummary":326,"conditions":327,"keywords":332,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":123},"100558150","dietary-intervention-on-atopy-100558150","NCT06547372","Dietary Intervention on Atopy","Inclusion Criteria:\n\n1. Presence of current, mild-to-moderate atopic dermatitis\u002Feczema at flexural areas\n2. 21 to 65 years of age (inclusive) at screening\n3. Must be English-literate and able to give informed consent in English\n4. Be residing in Singapore and will not be travelling outside of Singapore during the study period\n5. Reliable and willing to follow study procedures and be available for the duration of the study\n6. Non-smokers (tobacco and e-cigarette)\n7. Non-drinker (no regular or frequent consumption of alcohol)\n8. Overtly healthy with no pre-existing medical conditions (e.g., diabetes, hypertension, cancer, blood disorders, degenerative\u002Fliver\u002Fautoimmune\u002Fimmune\u002Frenal diseases, or psychiatric conditions)\n9. No food allergies to test foods\n10. No needle phobia\n11. Be willing to follow the instruction provided by the investigators on the use of any moisturiser, cosmetics, and\u002For topical cream on the skin throughout the entire duration of the study.\n\nExclusion Criteria:\n\n1. Concurrent participation in other research studies\n2. Pregnancy or lactating individuals\n3. Known or ongoing psychiatric disorders within 3 years\n4. Known severe nutritional deficiency\n5. Vegetarian\u002Fvegans (as meat will be included in the diet)\n6. Individuals who made a significant dietary change in the past 12 months\n7. Having a pre-existing dietary restriction that would interfere with the adherence to a whole diet meal\n8. Regular use of strong medication (western and\u002For traditional), therapies, and alternative medications\n9. Regular nutritional supplements in the past 12 months Regular consumption of oral contraceptive pills and\u002For steroid hormones\n10. Antibiotic use in the past 2 months\n11. Any long-term hospitalisation or surgery during the 6 months before enrolment in study\n12. Significant change in weight (+\u002F- 5.0%) during the past month\n13. History of bleeding diathesis or coagulopathy (or any bleeding disorders)\n14. Having donated blood of more than 500 mL within 4 weeks of study enrolment","65 Years",{"count":324,"type":21},110,[94],"Diet is a key determinant of overall health, with growing evidence associating dietary patterns with allergic diseases. Among these, atopic dermatitis (AD) is of particular interest as it often represents the earliest manifestation of the atopic triad. Investigating dietary interventions in AD therefore provides a relevant model to better understand how diet may influence the onset and progression of allergic disease more broadly.",[328,329,330,331],"Atopic Dermatitis","Atopic","Allergic Diseases","Allergic Rhinitis",[333,334,335,336,337,338,339,340,341,342,197,343],"Atopic dermatitis","My Healthy Eating Plate","eczema","healthy diet","diet","meals","foods","allergic","allergy","atopic","nutrients","2026-03-26",{"date":255,"type":43},{"date":347,"type":43},"2024-05-10",{"date":47,"type":21},{"name":49,"class":50},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":59,"sex":357,"minAge":89,"maxAge":186,"enrollmentInfo":358,"targetDuration":4,"studyType":92,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":375,"locationsCount":51},"100631436","project-sirt6-activator-100631436","NCT07500649","Project SIRT6 Activator","SIRT6 Activation to Improve Biological Age Measured by GrimAge in Pre-frail, Middle-aged to Older Men: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. 50-80 years males;\n2. Resident of Singapore (citizenship or permanent residency is not required);\n3. Prefrail according to Fried frailty phenotype score;\n4. English-literate who can understand, read and write in English;\n5. Individuals without severe cognitive impairment, as determined by PI judgment;\n6. Apparently healthy and non-smokers having not more than 2 of the following conditions. If the conditions are present they have to be stable:\n\n   * Hypertension,\n   * Hyperlipidemia,\n   * Hyperglycemia,\n   * Osteopenia\u002Fosteoporosis,\n   * Osteoarthritis,\n   * COPD,\n   * Type 2 diabetes.\n\nSubjects who agree to shave one day before each visit if he has dense facial hairs on their cheeks that could interfere with skin microbiome sampling.\n\nExclusion Criteria:\n\n1. Pre-existing or history of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke, peripheral vascular disease);\n2. Current cancer or non-stable chronic obstructive pulmonary disease (COPD);\n3. Use of anticoagulant medication;\n4. Consuming seaweed more than 3 times a week;\n5. Having hairiness, moles, tattoos, scars, irritated skin, etc. on the face which could influence the investigation;\n6. Having used within the 3 past weeks for more than 3 consecutive days any systemic or topical drugs related to antibiotics or having planned to use these treatments during the study;\n7. Having a positive serology for HIV, HEPATITIS B, HEPATITIS C\\*\n\n   \\*Subjects will undergo a serology test, which will be conducted at baseline and at the end of the intervention visit. Only for subjects who accepted to undergo skin microbiopsy sampling;\n8. Subject with any contra-indication for skin microbiopsies:\n\n   * hypersensitivity or any serious reaction to local anesthesia; (lidocaine\u002Fprilocaine), local antibiotics, and antiseptics,\n   * with inherited or acquired hemostasis disorders,\n   * having had any treatment which may affect the blood coagulation and hemostasis (anti-coagulant medications…),\n   * having a history of wound healing defects (hypertrophic scars, keloids…).","MALE",{"count":268,"type":21},[94],"The global ageing population is increasingly affected by age-related diseases, which are challenging healthcare systems. Current treatments often extend lifespan without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process could prevent or delay multiple diseases, enhancing healthspan. Fucoidan, a sulfated polysaccharide from brown macroalgae, is a safe dietary supplement with Sirtuin-6 (SIRT6) activating properties, which are linked to longevity. Clinical studies have shown that it reduces inflammatory markers associated with biological aging and frailty and influences DNA methylation in vitro and in vivo; however, its effects on human DNA methylation remain unknown.",[25],[25,363,364,365,366,367,368],"Geroscience","Fucoidan","SIRT6 Activator","DNA methylation","Healthspan","Epigenetic aging clock","2026-03-24",{"date":371,"type":43},"2026-03-30",{"date":373,"type":43},"2025-07-01",{"date":47,"type":21},{"name":49,"class":50},{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":16,"minAge":89,"maxAge":186,"enrollmentInfo":384,"targetDuration":4,"studyType":92,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":123},"100627898","exploratory-study-on-a-multi-nutrient-supplement-and-exercise-program-for-improving-health-markers-associated-to-longevity-in-pre-frail-adults-100627898","NCT07454616","Exploratory Study on a Multi-nutrient Supplement and Exercise Program for Improving Health Markers Associated to Longevity in Pre-frail Adults","A Single-arm Exploratory Study to Investigate the Feasibility to Develop a Composite Score That Encompasses Gut (Microbiome), Muscle, Immune, Cognition Outcomes Based on a 12-weeks Intervention of a Novel Multi-nutrient Supplement Containing Synbiotics, Combined With Supervised Exercise in Pre-frail Individuals Aged 50 - 80 Years Old.","RtM","Inclusion Criteria\n\n1. Singapore residents of all ethnic groups\n2. Adults aged 50-80 years (both male and female)\n3. Body mass index (BMI) ≥18 kg\u002Fm²\n4. Classified as Prefrailty according to Fried frailty criteria\n5. Willing and able to attend all data collection visits and to comply with the exercise and supplementation protocols.\n6. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Current use of supplements containing: Bifidobacterium longum 536 (BB536) like Kordel's BB536 bifidus; Bifidobacterium longum such as GniiB immunity; GOS (Galacto-oligosaccharides); FOS (Fructo-oligosaccharides); Inulin or any commercial healthy-aging powdered milk products\n2. BMI \\>30 kg\u002Fm2 3 Being on special diets including but not limited to ketogenic diets or diets prescribed by a healthcare professional\n\n4\\. Received any vaccination within the past 8 weeks. 5. Inition of new medication or use of medications affecting gastrointestinal function within the past 8 weeks, including but not limited to antibiotics or Proton pump inhibitors 6. Known allergies or intolerances, including, soy allergy; fibre allergy (e.g., GOS) or requirement for a fibre-free diet; fish allergy; Cow's milk protein allergy or lactose intolerance; galactosaemia 7. More than two unstable chronic conditions (e.g., hypertension, diabetes, hyperlipidemia, osteoarthritis, COPD) 8. Medical conditions for which probiotic use is contraindicated, including but not limited to immunocompromised individuals, astrointestinal failure or severe gastrointestinal disturbances (e.g., blood in stool), presence of a central venous catheter, open wounds following surgery 9. Contraindications to oral feeding, including gastrointestinal failure, complete intestinal obstruction, inability to access the gut or high loss intestinal fistulae 10. Known renal disease were unable to tolerate 2 servings per day. 11. Intake of supplemental calcium \\>500 mg\u002Fday or vitamin D \\>40 µg\u002Fday (1600 IU) from all sources, including diet and supplements 12. Use of medications that may interact with or impair absorption of milk products (e.g., tetracyclines) 13. Any other condition deemed by PI that may compromise participant safety and study compliance.",{"count":385,"type":21},40,[94],"Frailty is associated with biological changes in the gut microbiome and immune system, along with marked declines in physical and cognitive function, leading to an overall reduction in quality of life. Prefrailty represents an early stage where interventions may prevent or reverse these declines. This study aims to evaluate whether a 12-week combined Synbiotic enriched oral nutritional supplement and supervised exercise program can improve muscle strength and mass, gut microbiome composition, immune function, and cognitive performance in prefrail adults aged 50-80 years.",[273,25],[390,391,392,393,394],"Prefrail elderly","Gut microbiome","Nutritional supplementation","supervised exercise","Biological age markers","2026-03-03",{"date":397,"type":43},"2026-03-06",{"date":399,"type":43},"2025-09-22",{"date":401,"type":21},"2026-05-08",{"name":49,"class":50},{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":408,"eligibilityCriteria":409,"healthyVolunteers":59,"sex":16,"minAge":89,"maxAge":186,"enrollmentInfo":410,"targetDuration":4,"studyType":92,"phases":412,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":123},"100627658","precision-geromedicine-tailored-healthy-ageing-with-lifestyle-supplements-and-drugs-prometheus-100627658","NCT07451496","PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS)","PROMETHEUS","Inclusion Criteria:\n\n* Age 50-80 years (both male and female)\n* Relatively healthy and in stable health condition\n* Not engaged in regular resistance or aerobic training in the past 12 months (i.e., untrained)\n* VO₂peak below the 75th percentile for age- and sex-specific norms\n* Cognitive performance below 75th percentile on the NIH Toolbox Cognitive Function Battery\n* Willing and able to comply with exercise and supplementation protocols\n* English-literate (can read and understand English)\n* Provides written informed consent\n* Deemed to have mental capacity, as assessed by the Principal Investigator\n* Are able to attend all research visits for screening and research data collection at MD11, Yong Loo Lin School of Medicine, National University of Singapore\n\nExclusion Criteria:\n\n* Significant change in medication in the past 3 months\n* History of major cardiovascular disease (e.g., coronary artery disease, heart failure, stroke)\n* More than two unstable chronic conditions (e.g., hypertension, diabetes, osteoarthritis, COPD)\n* Known allergies to soy, shellfish\u002Fseaweed, mushrooms, or supplement ingredients\n* Participation in another interventional clinical trial\n* Current use of any study-related supplement unless willing to stop\n* Any medical, psychiatric, or cognitive condition deemed by the PI to jeopardise safety or compliance\n* Pregnant or planning pregnancy during the study period\n* Any conditions deemed by PI that jeopardize the safety or study compliance",{"count":411,"type":21},20,[94],"As the population ages, the growing prevalence of age-related diseases is creating substantial challenges for healthcare systems worldwide. Current therapeutic strategies often target individual diseases and decrease mortality without improving healthspan. The geroscience hypothesis suggests that targeting the ageing process itself could prevent, delay, or manage the severity of multiple age-related diseases concurrently, thereby improving overall healthspan and reducing healthcare burdens.\n\nEmerging research highlights several interconnected hallmarks of aging, such as mitochondrial dysfunction, chronic inflammation, impaired autophagy, and immune dysregulation, as modifiable through targeted interventions. Precision geromedicine represents a paradigm shift in addressing these processes, combining baseline diagnostics with individualized treatment strategies that adapt over time based on patient response. This approach integrates lifestyle modifications, dietary supplements, and pharmacological agents to optimize physical, cognitive, and immune function across the lifespan .",[415],"Ageing",[417,418,364,419,420,421,422,25,363,366,367,368],"Whey Protein supplementation","Creatine","NMN","Multivitamin","Ergothioneine","Urolithin A","2026-02-28",{"date":425,"type":43},"2026-03-05",{"date":427,"type":43},"2025-09-29",{"date":429,"type":21},"2026-06-30",{"name":49,"class":50},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":59,"sex":16,"minAge":438,"maxAge":213,"enrollmentInfo":439,"targetDuration":4,"studyType":92,"phases":440,"briefSummary":441,"conditions":442,"keywords":444,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":458,"locationsCount":51},"100621000","altered-non-visual-photoreception-in-patients-with-glaucoma-impacts-on-sleep-alertness-mood-and-cognition-100621000","NCT07364929","Altered Non-Visual Photoreception in Patients With Glaucoma: Impacts on Sleep, Alertness, Mood, and Cognition","EyeQ","Inclusion Criteria:\n\n* Patients with glaucoma must meet all of the inclusion criteria to participate in this study.\n\n  * Patients diagnosed with primary open-angle glaucoma (POAG), as indicated by Humphrey Visual Field (HVF) mean deviation (VFMD) scores better than -12 dB in at least one eye during their most recent clinic visit.\n  * Patients having spared central vision.\n  * Patients aged 45 to 75 years old.\n  * Patients with a best-corrected visual acuity better than 6\u002F12\n  * English-speaking patients\n\nHealthy controls must meet all of the inclusion criteria to participate in this study:\n\n* Participants aged 50 to 70 years old.\n* Participants with a best-corrected visual acuity better than 6\u002F12\n* Normal ophthalmic examination\n* English-speaking participants\n\nExclusion Criteria:\n\n* All subjects (patients and controls) meeting any of the exclusion criteria at baseline will be excluded from participation:\n\n  * Participants with myopia exhibiting a refractive error exceeding -8.00 diopters (D)\n  * Participants with a history of complicated previous intraocular surgery\n  * Participants taking alpha-adrenergic agonist eye drops or other systemic medications or drugs that could affect the pupillary response\n  * Participants with any past or current ocular condition (i.e., age-related retinal diseases (e.g., age-related macular degeneration), retinal pigment epithelium diseases (e.g., Best's disease), diabetic retinopathy, or other optic or generalized neuropathies, significant ocular trauma, or any eye condition affecting fixation (eg. Nystagmus)).\n  * Participants diagnosed with cataracts at NS3+ (Nuclear Sclerosis) and above, as well as those with Posterior Subcapsular (PSC) cataracts\n  * Participants with clinically diagnosed psychiatric or neurologic disorders, including cognitive impairment or dementia\n  * Participants with diagnosed mood disorders\n  * Participants engaged in night shift work within the past three months, are currently using sleeping pills, or have recently travelled across timezones within a month prior to the study\n  * Participants with obstructive sleep apnea\n  * Participants with abnormal auditory function\n  * Participants with impaired color vision\n  * Pre-menopausal women (last menstrual period \\\u003C 1 year) (If applicable)\n  * Patients having unilateral glaucoma, congenital glaucoma, non-glaucomatous optic neuropathy, abnormal central vision\n  * Diabetics on treatment","45 Years",{"count":215,"type":21},[94],"The goal of this study is to understand how light sensitivity in the eye affects sleep, mood, alertness, and cognition in adults with glaucoma compared to healthy individuals aged 45-75 years.\n\nThe main questions it aims to answer are:\n\n1. Do patients with glaucoma experience poorer sleep, mood, alertness, and cognitive function than age-matched healthy adults?\n2. Are these changes related to reduced light sensitivity in special retinal cells called intrinsically photosensitive retinal ganglion cells (ipRGCs), lost in glaucoma?\n3. Can exposure to safe, full-spectrum indoor light help improve these functions?\n\nResearchers will compare patients with glaucoma and age-matched healthy controls to see if differences in light sensitivity can explain changes in non-visual light responses (i.e., sleep, mood, alertness, and cognition) and whether full-spectrum light exposure can enhance alertness and wellbeing.\n\nParticipants will:\n\n1. Complete eye exams and baseline questionnaires about their sleep, daytime sleepiness, mood, and wellbeing.\n2. Wear a wrist-worn device for 8-16 days to record their sleep patterns and light exposure.\n3. Visit the laboratory for cognitive and attention tests following exposure to two lighting conditions (randomized, cross-over):\n\n   * Standard indoor light (\\~300 lux)\n   * Full-spectrum light (\\~1000 lux)\n\nThis study will help researchers understand how glaucoma affects the brain beyond vision and explore whether light-based interventions can improve quality of life for people living with glaucoma.",[443],"Glaucoma",[445,446,447,448,449,450,451],"light","glaucoma","brain","sleep","mood","cognition","alertness","2026-01-18",{"date":454,"type":43},"2026-01-23",{"date":456,"type":43},"2025-09-05",{"date":78,"type":21},{"name":49,"class":50},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":186,"enrollmentInfo":467,"targetDuration":4,"studyType":92,"phases":469,"briefSummary":472,"conditions":473,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":476,"lastUpdatePostDateStruct":477,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":123},"100614626","phase-2-role-of-glp1-ra-dulaglutide-on-severe-intracranial-atherosclerosis-100614626","NCT07282041","Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis","Role of Glucagon-like Peptide 1 Receptor Agonist (GLP1 RA) Dulaglutide on Cerebral Hemodynamics In Patients With Severe and symptomAtic steNosis of inTracranial Internal Carotid Artery or Middle Cerebral Artery With Impaired Cerebral Vasodilatory Reserve- an Open-label Randomised Clinical Trial (RADIANT)","RADIANT","Inclusion Criteria:\n\n* Adult patients aged 21 - 80 years old inclusive,\n* Able to provide consent,\n* Score 3 or less on the Modified Rankin Score (mRS),\n* Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA\n\nExclusion Criteria:\n\n* Chronic kidney disease stage 5 (eGFR\\\u003C15 mL\u002Fmin) or on dialysis,\n* Cancer diagnosed within past 3 years,\n* Currently being planned for coronary or carotid artery revascularization,\n* History of previous pancreatitis,\n* History of medullary thyroid cancer,\n* Atrial fibrillation,\n* Any other condition likely to limit protocol compliance (judged by investigator).\n* For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants' medical condition. For those on Dipeptidyl peptidase-4 (DPP IV) inhibitor, this agent will be discontinued if the patient is randomised to the intervention group.\n* Known allergies to Acetazolamide.\n* Women who are pregnant or breastfeeding.",{"count":468,"type":21},130,[470,471],"PHASE2","PHASE3","One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).\n\nIn this open label randomised clinical trial, patients with recently symptomatic and severe stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA) with impaired cerebral vasodilatory reserve (CVR) will be included. CVR will be measured with transcranial Doppler (TCD) breath holding index and acetazolamide-challenged single photon emission computed tomography (SPECT). Patients meeting the eligibility criteria would be randomised to receive best medical therapy (according to the international guidelines and institutional practices) or Dulaglutide subcutaneous injection (0.75mg and titrating to 1.5mg, if indicated) once a week, in addition to the best medical therapy. CVR will be measured again at the completion of 1 year. MRI of the brain will be repeated to evaluate any new ischaemic brain lesions. All patients would be followed up for two years for cerebral ischaemic events.\n\nThe investigators hypothesize that addition of GLP1 RA therapy would lead to a reduction of at least 4 units in CVR on SPECT as compared to best medical therapy.",[474,475],"Intracranial Atherosclerosis","Stroke, Ischemic","2025-12-16",{"date":478,"type":43},"2025-12-23",{"date":480,"type":43},"2025-12-17",{"date":482,"type":21},"2030-12-01",{"name":49,"class":50},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":59,"sex":16,"minAge":491,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":92,"phases":495,"briefSummary":496,"conditions":497,"keywords":503,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":524},"100564604","optimizing-light-exposure-for-myopia-prevention-and-control-lightspan-100564604","NCT06631339","Optimizing Light Exposure for Myopia Prevention and Control (LightSPAN)","LightSPAN","Inclusion Criteria:\n\n* Subject must meet all the inclusion criteria below to participate in this study.\n\n  1. Written Informed Consent form from parent \u002F legal guardian and assent from child subject has been obtained\n  2. Is between 7 to 10 years of age at start of study intervention which is 2 January 2025 or 1 January 2026\n  3. Studying in either Primary 2 or 3 classes of the participating school(s) in academic year 2025 or 2026.\n  4. Presenting visual acuity or best corrected visual acuity (BCVA) better or equal to LogMAR 0.2 (equivalent to Snellen 6\u002F9 or better) in each eye\n  5. Normal Intraocular pressure (not more than 21mmHg)\n  6. No ocular conditions (e.g., optic nerve disease, glaucoma, retinal diseases) except for refractive error.\n  7. No ocular conditions affecting the accuracy of the ophthalmic examinations\n  8. In good general health with no significant systemic diseases that may affect eye health\n\n     Exclusion Criteria:\n* All subjects meeting any of the exclusion criteria at baseline will be excluded from participation.\n\n  1. Previous or ongoing myopia control treatment (including but not limited to orthokeratology, atropine, pirenzepine, myopia control spectacle and contact lenses, light therapy)\n  2. Ongoing participation in other myopia prevention and control research trials\n  3. Any systemic or neurologic diseases (e.g. cancer, epilepsy, Kawasaki disease) known to affect eye health or make the participant vulnerable to the ophthalmic examinations (e.g., light flash)\n  4. Any other conditions precluding adherence to the protocol including unwillingness to refrain from myopia control treatment for the duration of the study","7 Years","10 Years",{"count":494,"type":21},396,[94],"The goal of this clinical trial is to evaluate whether the optimization of daily exposure to light in primary school children can lead to better myopia prevention and control. The trial also aims to better understand the impact of light exposure on sleep and cognitive performance in children.\n\nThis trial has 3 arms namely, (1) a technical intervention arm, (2) a digital intervention arm, and (3) a control arm.\n\n1. technical intervention - which involves changing of classroom lighting in primary schools to ceiling lights that mimic the spectral composition of sunlight and fluctuates in intensity. Parents of children within that arm will have a sham smart-phone application (s-LightUP)\n2. digital intervention - which involves standard classroom lighting and giving parents an interventional smart-phone application (i-LightUP) that will be coupled with their child's light and activity sensor (wrist worn device ). The interventional app will provide individually tailored recommendation based on their children's behaviour (data feedback that is collected from the light and activity monitoring watch). The interventional app would then send reminder prompts\u002Fnotifications to encourage parents help their children achieve required amounts of myopia-preventive light quantum target set per day.\n3. Standard care or control group which involves standard classroom lighting and parents having a sham smart-phone application (s-LightUP)\n\nParticipants will:\n\n* be randomised to receive either no intervention (control group), technical intervention (light intervention that mimics sunlight) or digital intervention (parents having an app that syncs with child's light and activity sensor which will provide feedback to parents to encourage and recommends increment of outdoor activities and hours).\n* have their myopia progression monitored every 6 monthly and cognitive assessment done once every 3 months over a year.\n* wear the light and activity sensor watches throughout the 1-year study period as much as possible (minimum 1 week per month) except for wet water activities such as swimming, diving and showering for research data collection purpose.",[498,499,500,501,502],"Myopia","Light; Therapy, Complications","Myopia Progression","Short-Sighted","Myopia; Refractive Error",[504,505,498,506,507,508,509,510,511,512,197,513,514,515],"Light Exposure","Digital Intervention","Myopia Prevention","Cognition","Light Intervention","Behaviour changing phone application","Classroom","School-based","School","Primary School","Light therapy","Myopia-control","2025-09-21",{"date":518,"type":43},"2025-09-23",{"date":520,"type":43},"2024-10-21",{"date":522,"type":21},"2027-01-26",{"name":49,"class":50},5,{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":4,"enrollmentInfo":532,"targetDuration":4,"studyType":92,"phases":533,"briefSummary":534,"conditions":535,"keywords":540,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":123},"100603312","navigating-advanced-illness-goals-and-treatment-with-digital-engagement-navigate-100603312","NCT07134881","Navigating Advanced Illness Goals And Treatment With Digital Engagement (NAVIGATE)","Navigating Advanced Illness Goals And Treatment With Digital Engagement (NAVIGATE): A Randomised Control Trial","1\\. Patient Participants Inclusion Criteria:\n\n1. Singapore resident aged 21years and above,\n2. patient able to identify one main caregiver in the care and medical decision-making for the patient;\n3. patient able to communicate in either English, Chinese, Malay or Tamil;\n4. patient meeting one of the following illness criteria: 4a. Patients with brain tumours: histological and\u002For radiological diagnosis of glioma or brain metastases.\n\n4b. Patients with spontaneous intracerebral haemorrhage (SICH) based on radiological diagnosis of SICH on baseline computed-tomographic scans.\n\n4c. Patients with CKD Stage 4 and 5, identified at G4 or G5 of CKD, glomerular filtration rate (GFR) 30 ml\u002Fmin or less, inclusive of kidney failure on kidney replacement therapy; and (5) Physicians assessment that ACP is appropriate for the patient by physicians.\\* (\\*) The attending clinicians may base the assessment of ACP appropriateness on several factors in addition to high mortality risk. As a baseline, clinicians are asked to base their assessment of high mortality risk using the validated \"Surprise\" question.\n\n2\\. Patient participants Exclusion Criteria:\n\n1. Patients unable to identify a caregiver who is a medical decision-maker,\n2. Patients are currently or was previously healthcare workers; or\n3. Patients are diagnosed with dementia or deemed cognitively impaired as determined by the Abbreviated Mental Test.\n\n3\\. Caregiver Participants Inclusion Criteria:\n\n1. caregivers are identified as a medical decision-maker for the patient\n2. Singapore resident aged 21 years and above; and\n3. able to communicate in English\n\n4\\. Caregiver Participants Exclusion Criteria:\n\n1. caregivers are currently or were previously healthcare workers;\n2. caregivers not involved in primary care of the patient (including providing care to the patient, supervision of care, or involved in making decisions regarding treatment the patient receives); or\n3. caregivers diagnosed with dementia.",{"count":164,"type":21},[94],"The goal of this two-armed, parallel-design, pre-\u002Fpost-intervention assessment clinical trial is to learn if a digital and interactive website helps to improve advance care planning (ACP) engagement among caregivers of patients with serious illness. The main questions it aims to answer are:\n\nDoes the website increase ACP engagement of caregivers of patients with serious illness? Researchers will compare the digital and interactive website to the usual care (a digital booklet) to see if the digital intervention works to improve ACP engagement among caregivers.\n\nParticipants who are caregivers will:\n\n* Be introduced to a digital website and asked to explore the site over the course of the study.\n* Complete four self-administered questionnaires (baseline, one-week, six-week, and six-month).\n\nParticipants who are patients will not have any intervention assigned and will only have their observational data collected through four interviewer-administered questionnaires (baseline, one-week, six-week, and six-month)",[536,249,537,538,539],"Paliative Care","Digital Education Interventions","Values, Social","Goals of Care",[541,542,543,544,545],"randomised control trial","digital intervention","advance care planning","goals of care","palliative care","2025-09-12",{"date":548,"type":43},"2025-09-15",{"date":550,"type":43},"2025-08-27",{"date":552,"type":21},"2027-07-31",{"name":49,"class":50},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":4,"eligibilityCriteria":560,"healthyVolunteers":59,"sex":16,"minAge":212,"maxAge":4,"enrollmentInfo":561,"targetDuration":4,"studyType":92,"phases":563,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":582,"leadSponsor":584,"locationsCount":123},"100605373","whatsapp-intervention-for-seniors-digital-and-cognitive-management-wisdom-100605373","NCT07161674","WhatsApp Intervention for Seniors' Digital and Cognitive Management (WISDOM)","WhatsApp Intervention for Seniors' Digital and Cognitive Management (WISDOM): a Mixed-methods Pilot Study","Inclusion Criteria:\n\n* Age 60 years and above\n* Own a smartphone\n* Received up to primary school education or lesser\n* Able to converse and read English or Mandarin\n\nExclusion Criteria:\n\n* Diagnosed with dementia or at risk of dementia (MoCA) ≤ 23\u002F24",{"count":562,"type":21},140,[94],"The goal of this clinical trial is to learn if a digital health literacy program using mobile phone chat-based application called WISDOM (WhatsApp Intervention for Seniors' Digital and cOgnitive Management) can help older adults in Singapore with fewer resources improve their digital health skills and support brain health.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to run WISDOM in senior centres, and will participants join and stay in the program?\n* Does WISDOM help older adults find and use online health information?\n* Does WISDOM help older adults make health decisions and impact brain functions?\n* What do participants think about WISDOM, and how can it be improved?\n\nResearchers will compare two groups:\n\n* WISDOM group: Participants will join a 6-week program with face-to-face learning sessions and WhatsApp activities about digital health skills. Extra support will be given if needed.\n* Control group: Participants will continue with their usual activities at the senior centres.\n\nParticipants in the WISDOM group will:\n\n* Join weekly face-to-face sessions for 6 weeks\n* Use WhatsApp to complete learning activities",[507,566,567],"Aged","Digital Health Literacy",[569,570,571,276,572,573,574,197,575,576,577],"Digital health literacy","Cognitive health","Cognitive function","Aging population","Community-based intervention","Health information seeking","Feasibility study","Mixed methods study","WhatsApp intervention","2025-09-02",{"date":580,"type":43},"2025-09-09",{"date":548,"type":21},{"date":583,"type":21},"2027-02-28",{"name":49,"class":50},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":322,"enrollmentInfo":591,"targetDuration":4,"studyType":92,"phases":592,"briefSummary":593,"conditions":594,"keywords":596,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":603,"lastUpdatePostDateStruct":604,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":123},"100601875","a-pilot-return-to-work-cognitive-intervention-after-stroke-100601875","NCT07116187","A Pilot Return-to-Work Cognitive Intervention After Stroke","Inclusion Criteria (for stroke survivors):\n\n* Between 21 to 65 years old\n* Ability to provide informed consent\n* Consent to recording \u002F photo-taking\n* Living in the community with at least three months after stroke\n* Looking to return to work or switch jobs after stroke\n* No significant aphasia or physical disability issues which will impede them from performing cognitive tasks in the interventions and assessments\n* No major psychiatric illnesses\n* Able to understand and converse in English\n* Score on MoCA ≤22 and\u002For SDMT ≤13 (for those educated ≤6 years) or SDMT ≤32 (for those educated \\>6 years)\n* Meet criteria for Mild Cognitive Impairment based on the Vascular Dementia Battery\n\nInclusion Criteria (for caregivers):\n\n* At least 21 years old\n* Ability to provide informed consent\n* Consent to recording \u002F photo-taking\n* Staying with or having knowledge of the stroke survivor's functioning\n* No major psychiatric illnesses\n* Able to understand and converse in English\n\nExclusion Criteria (for stroke survivors):\n\n* Less than 21 years old\n* More than 65 years old\n* Unable to provide informed consent\n* Refuse recording\n* Not living in the community and having less than three months after stroke\n* Significant aphasia or physical disability issues which will impede them from performing cognitive tasks in the interventions and assessments\n* Major psychiatric illnesses\n* Not able to understand and converse in English\n\nExclusion Criteria (for caregivers):\n\n* Less than 21 years old\n* Unable to provide informed consent\n* Refuse recording\n* Not staying with or not having knowledge of the stroke survivor's functioning\n* Major psychiatric illnesses\n* Not able to understand and converse in English",{"count":91,"type":21},[94],"This study addresses the growing burden of stroke in Singapore and highlights the lack of rehabilitation services for return to work after stroke. Despite functional physical recovery, many stroke survivors experience persistent impairments that hinder return-to-work. To bridge this gap, the study will implement a community-based brain health programme targeting cognitive and vocational outcomes in stroke survivors. Caregivers will also be included due to their critical support role. The study will assess the intervention's feasibility, acceptability, and its impact on cognitive function, return-to-work, neuroplasticity, psychosocial health, fatigue, and self-care.",[595],"Stroke",[507,597,598,599,600,601,602],"Return-to-work","Rehabilitation","Intervention","Community","Stroke survivors","Caregivers","2025-08-19",{"date":605,"type":43},"2025-08-26",{"date":607,"type":43},"2025-08-08",{"date":609,"type":21},"2026-12-31",{"name":49,"class":50},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":4,"eligibilityCriteria":617,"healthyVolunteers":59,"sex":16,"minAge":212,"maxAge":618,"enrollmentInfo":619,"targetDuration":4,"studyType":92,"phases":621,"briefSummary":622,"conditions":623,"keywords":628,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":123},"100599184","dose-response-effect-of-community-dance-programme-100599184","NCT07081191","Dose-response Effect of Community Dance Programme","Dose-response Effect of Community Dance Programme on the Physical, Cognitive, Psychosocial Health of Pre-frail and Mildly Frail Older Adults: A Cluster Randomised Trial With Co-design Approach and Process Evaluation","Inclusion Criteria:\n\n* Aged 60 to 85.\n* Able to understand and communicate in either English or Mandarin.\n* Able to give consent to participate.\n* Able to commit for three months and able to achieve at least an attendance rate of 75% for the dance program.\n* Lives within the community setting.\n* Abbreviated Mental Test (AMT) score\\>= 8\n* Obtain a score of less than or equal to 7 in Edmonton Frail Scale - Acute Care or less than or equal to 5 in Clinical Frailty Scale\n* Able to ambulate with minimal assistance\n* Willing to avoid other physical exercise during the interventional period.\n* Consent to video and photography of the dance sessions and audio recording of the FGDs.\n\nExclusion Criteria:\n\n* Abbreviated Mental Test (AMT) score of less than 8.\n* A score of more than 7 on the Edmonton Frail Scale - Acute Care or a score of more than 5 on Clinical Frailty Scale\n* Diagnosed with severe cognitive or psychiatric disorders.\n* Have severe hearing or vision impairments\n* Have medical conditions which results in limitation of dancing (e.g. walking aids, wheelchair etc.)\n* Older adults with serious chronic diseases (e.g. postural hypotension etc.)\n* Registered in any other dance group during the intervention period","85 Years",{"count":620,"type":21},284,[94],"The goal of this interventional study is to examine the dose-response effect of Community Dance Programme (CDP) on the physical, cognitive and psychological health of pre-frail and mildly frail community-dwelling older adults. The main questions it aims to answer are:\n\nHypothesis 1: Two sessions of CDP per week (75 minutes each) significantly increase the physical outcomes (i.e. CFS, EFS, SPPB, grip strength) of community-dwelling older adults as compared to one session of CDP per week.\n\nHypothesis 2: Two sessions of CDP per week significantly improve the cognitive outcomes (i.e. MoCA, SDMT) of community-dwelling older adults as compared to one session of CDP per week.\n\nHypothesis 3: Two sessions of CDP per week significantly improve the psychosocial outcomes (i.e. WHOQOL-OLD, De Jong Giervald Loneliness Scale, GPIC scale, SHS, SSQ) of community-dwelling older adults as compared to one session of CDP per week.\n\nIntervention: The participants will be asked to attend two sessions of CDP per week for 12 weeks at their respective Active Ageing Centres (AACs).\n\nActive control: The participants will be asked to attend one session of CDP per week for 12 weeks AACs.\n\n* The participants will be asked to go to the AACs at baseline and after 12 weeks of CDP intervention for the collection of data.\n* The participants will be asked to wear fitness trackers to track their heart rates during the CDP sessions to ensure that the dance curriculum is kept within the moderate intensity.",[624,625,626,627],"Dance","Older Adults","Frailty at Older Adults","Active Ageing",[629,276,272],"dance","2025-07-23",{"date":632,"type":43},"2025-07-28",{"date":634,"type":43},"2025-05-07",{"date":636,"type":21},"2027-08",{"name":49,"class":50},{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":59,"sex":16,"minAge":212,"maxAge":618,"enrollmentInfo":645,"targetDuration":4,"studyType":92,"phases":647,"briefSummary":648,"conditions":649,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":654,"leadSponsor":656,"locationsCount":123},"100599191","precision-stratification-for-frailty-and-cognitive-decline-100599191","NCT07081282","Precision Stratification for Frailty and Cognitive Decline","Precision Care Pathway Through Frailty and Cognitive Assessment Among Older Adults and Development of Care4Senior App, Intensive Aerobic Resistance Training and Brain Health Program in the Community","Inclusion Criteria:\n\n1. Older Adults Aged 60 to 85 years old\n2. Living in the community\n3. Formally diagnosed with at least one chronic disease\n4. Able to communicate in either English or Mandarin\n\nExclusion Criteria:\n\n1. Severe vision or hearing impairment\n2. Diagnosed with severe cognitive impairment (e.g. dementia)\n3. Diagnosed with severe psychiatric disorders (e.g. psychotic disorders, major depressive disorder)",{"count":646,"type":21},252,[94],"The Care4Senior mobile Application, Intensive Aerobic Resistance Training and Brain Health (CIRTAB) trial aim to test the effectiveness of an exercise, cognitive and lifestyle intervention amongst older adults over a 12-weeks trial period to prevent frailty and promote social bonding.",[272,650],"Cognitive Decline","2025-07-15",{"date":630,"type":43},{"date":373,"type":43},{"date":655,"type":21},"2027-05-31",{"name":49,"class":50},{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":16,"minAge":131,"maxAge":664,"enrollmentInfo":665,"targetDuration":4,"studyType":92,"phases":667,"briefSummary":668,"conditions":669,"keywords":671,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":123},"100591271","digital-positive-affect-intervention-study-100591271","NCT06978257","Digital Positive Affect Intervention Study","Protocol of a Two-Arm Randomized Controlled Trial (RCT) of Digital Positive Affect Intervention Study","Inclusion criteria\n\n* Adults aged between 21 and 64 years\n* Proficient in written and spoken English\n* Ability to provide informed consent\n* Scores between 5 and 14 on the Generalized Anxiety Disorder-7 (GAD-7) scale OR\n* Scores between 5 and 19 on the Patient Health Questionnaire-9 (PHQ-9) scale\n* Scores below 6 on the Altman Self-Rating Mania (ASRM) scale\n* Possess an active smartphone with a valid Singapore phone number\n* Mainly based in Singapore, within the next 15 months Exclusion criteria\n* Failure to meet the above inclusion criteria\n* Significant suicidal thoughts within the past two weeks, defined as self-reporting \"more than half the days\" or \"nearly every day\" on the PHQ-9 Item 9.\n* Received psychiatric diagnoses of bipolar disorder, disorders of psychosis, severe clinical anxiety, or severe clinical depression.\n* Severe clinical anxiety (scores of 15 to 21 on the GAD-7)\n* Severe clinical depression (scores of 20-27 on the PHQ-9)","64 Years",{"count":666,"type":21},2400,[94],"Anxiety and depression are highly prevalent mental health disorders that impose a significant burden on individuals and public health systems worldwide (GBD 2019 Mental Disorders Collaborators, 2022). Although many existing treatments focus on symptom reduction through targeting negative emotions, fewer interventions specifically enhance positive emotional experiences, despite growing evidence that low positive affect is a key feature of both anxiety and depression. Face-to-face psychologist-led positive affect therapy (PAT) is a promising intervention that aims to cultivate positive emotions, engagement, and meaning, potentially leading to greater improvements in emotional well-being than traditional approaches (Craske et al., 2019). However, empirical evaluations of digitally-delivered, asynchronously-coached, scalable versions of the PAT remain limited (Craske et al., 2024; Firth et al., 2017). The present study thus aims to investigate the comparative efficacy of a digital positive affect intervention (PAI) in reducing symptoms of anxiety and depression and enhancing overall mental health outcomes. We utilize a two-arm randomized controlled trial (RCT) design to investigate the effectiveness of a six-week digitally delivered positive affect intervention (vs. self-monitoring active control; Zainal \\& Newman, 2023) in reducing self-reported symptoms of anxiety and depression, as well as other secondary psychosocial outcomes, including sleep quality, quality of life, and emotion regulation. The treatment program comprises weekly evidence-based therapeutic material delivered online, and daily mental health (MH) mobile application prompts delivered thrice a day for the 6-week treatment period, based on evidence-based positive affect therapy principles. The active comparator comprises self-monitoring MH mobile application prompts for the 6-week treatment period. All participants will be assessed on several psychosocial outcomes at mid-treatment, post-treatment, and at 3-, 6-, and 12-month follow-up. The study hypothesizes that participants randomized to the digital PAI will experience greater improvement in anxious and depressive symptoms both immediately after treatment and up to a year later, compared to the self-monitoring MH app. Findings will contribute to growing evidence that digital PAI is an efficacious and feasible treatment to target and enhance positive emotions and related mental health outcomes in adults experiencing anxiety and depression.",[670],"Mild to Moderate Anxiety and Depression",[144,145],"2025-06-23",{"date":674,"type":43},"2025-06-26",{"date":676,"type":43},"2025-04-01",{"date":678,"type":21},"2029-06-30",{"name":49,"class":50},{"id":681,"slug":682,"hasResults":12,"nctId":683,"briefTitle":684,"officialTitle":685,"acronym":686,"eligibilityCriteria":687,"healthyVolunteers":12,"sex":16,"minAge":61,"maxAge":4,"enrollmentInfo":688,"targetDuration":4,"studyType":92,"phases":690,"briefSummary":692,"conditions":693,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":699,"lastUpdatePostDateStruct":700,"startDateStruct":702,"completionDateStruct":704,"leadSponsor":706,"locationsCount":707},"100593254","phase-4-optimising-treatment-for-severe-gram-negative-bacterial-infections-100593254","NCT07004049","Optimising TREATment for Severe Gram-Negative Bacterial Infections","TREAT-GNB [CR-GNB]","TREAT-GNB","Inclusion Criteria:\n\nA: Bloodstream infections\n\na) Suitable for at least 2 antibiotic regimens in the site randomisation list\n\n1. Growth of Gram-negative bacilli identified from blood culture(s)\n2. Receiving or planning to receive intravenous antibiotics\n3. Expected time from blood culture sampling to randomisation is ≤ 96 hours.\n\nOR\n\nB: Ventilator-associated pneumonia \u002F hospital-acquired pneumonia a) Suitable for at least 2 antibiotic regimens in the site randomisation list b) Infection syndrome definitions\\^( (US Centers for Disease Control and Prevention National Healthcare Safety Network)3: i) At least one of the following:\n\n1. temperature \\> 38 °C\n2. white blood cell count ≥ 12,000 cells\u002Fmm3 (12 x 109\u002FL, 12 x 103\u002FµL) or ≤ 4,000 cells\u002Fmm3 (4 x 109\u002FL, 4 x 103\u002FµL)\n3. altered mental status with no other causes in \\> 70 years old; AND ii) Two or more chest imaging tests demonstrating at least one of the following:\n\n1\\) new and progressive OR progressive and persistent infiltrate 2) new and persistent OR progressive and persistent consolidation 3) new and persistent OR progressive and persistent cavitation; AND iii) At least two of the following:\n\n1. new onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased in suctioning requirements\n2. new onset or worsening tachypnoea or dyspnoea\n3. rales or bronchial breath sounds\n4. worsening gas exchange defined by oxygen desaturations (e.g., PaO2\u002FFiO2 \\\u003C 240), increased oxygen requirements or increased ventilation demand.\n\n   c) Hospital admission \\> 48 hours d) Predominant growth of Gram-negative bacilli identified from respiratory tract specimen(s)\\*; e) Receiving or planning to receive intravenous antibiotics f) Expected time from respiratory culture sampling to randomisation is ≤ 96 hours\n\n   AND\n\n   C: CR-GNB antibiotic backbone domain\n\n   a) Gram-negative bacilli belonging to Acinetobacter baumannii-calcoaceticus complex, Pseudomonas aeruginosa or Enterobacterales b) Carbapenem resistance in isolate detected - i) Phenotypically via conventional microbiology testing: meropenem \u002F imipenem \u002F ertapenem resistance; OR ii) Genotypically via PCR or next generation sequencing: presence of genes associated with carbapenemase production (eg. blaNDM, blaKPC, blaIMP, blaIMI, blaVIM, blaOXA-48-like).\n\n   Exclusion Criteria:\n   1. Treating team deems enrolment in the study is not in the best interest of the patient\n   2. Patient is on end-of-life care\n   3. Patient is incarcerated in a correctional facility\n   4. Participation in any interventional study activities outlined in the TREAT-GNB study within the last 90 days\n   5. Pregnant women and children\n\n      OR\n   6. Polymicrobial bloodstream infection",{"count":689,"type":21},600,[691],"PHASE4","TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria.\n\nIn the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.",[694,695,696,697,698],"Bloodstream Infection","Ventilator Associated Bacterial Pneumonia","Hospital Acquired Bacterial Pneumonia","Carbapenem Resistant Bacterial Infection","Multidrug Resistance","2025-05-26",{"date":701,"type":43},"2025-06-04",{"date":703,"type":43},"2025-04-21",{"date":705,"type":21},"2028-12-31",{"name":49,"class":50},41,{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":713,"acronym":4,"eligibilityCriteria":714,"healthyVolunteers":59,"sex":16,"minAge":131,"maxAge":186,"enrollmentInfo":715,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":717,"conditions":718,"keywords":724,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":730,"lastUpdatePostDateStruct":731,"startDateStruct":733,"completionDateStruct":735,"leadSponsor":737,"locationsCount":123},"100575657","associations-between-dietary-intake-and-cardiometabolic-and-gut-microbiota-outcomes-100575657","NCT06775132","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes","Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes in Singapore Adults","Inclusion Criteria:\n\n1. Able to give informed consent\n2. Adults 21-80 years old\n3. English-literate\n4. Have venous access sufficient to allow for blood sampling as per the protocol\n5. No drastic change of diet for the past 1 year\n6. If taking medication, has been consistently taking antihypertensive\u002Fcholesterol-lowering\u002Ftype-2 diabetic medication for more than 5 years prior to starting the study.\n\nExclusion Criteria:\n\n1. Taking dietary supplements and fermented foods, which may impact the gut microbiota (e.g. antibiotics, prebiotics, probiotics, yogurt, kimchi) 2 months before starting the 1st study visit only.\n2. Taking dietary supplements or medications, which may impact sleep outcomes (e.g. Nutritional Shakes (e.g. Ensure), tryptophan, 5-hydroxytryptophan or melatonin supplementations) 1 month before starting the study.\n3. Taking dietary supplements which may impact the eye outcomes (e.g. Vitamin A, vitamin A-containing multivitamin) 2 months before starting the study.",{"count":716,"type":21},240,"This cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in Singapore adults.",[719,720,721,722,723],"Cardiometabolic Risk Factors","Gut -Microbiota","Skin Condition","Cognitive Ability, General","Sleep Quality",[725,726,727,728,729],"Endothelial progenitor cells","Gut microbiota","Cardiovascular diseases risk factors","MoCA","Advanced glycation end products","2025-05-19",{"date":732,"type":43},"2025-05-21",{"date":734,"type":43},"2025-02-03",{"date":736,"type":21},"2025-12-30",{"name":49,"class":50},""]